Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19

Published:2021-01 Issue: Volume:329 Page:87-95
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Lai Samuel K.,McSweeney Morgan D.,Pickles Raymond J.

Funder

National Institutes of Health

National Science Foundation

National Center for Advancing Translational Sciences

David and Lucile Packard Foundation

Eshelman Institute for Innovation, University of North Carolina at Chapel Hill

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference100 articles.

1. High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics;Gérard;Nat. Biotechnol.,2020

2. Microfluidic single-cell technology in immunology and antibody screening;Seah;Mol. Asp. Med.,2018

3. Single-cell droplet microfluidic screening for antibodies specifically binding to target cells;Shembekar;Cell Rep.,2018

4. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization;Chakraborti;Virol. J.,2005

5. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential;Coughlin;Rev. Med. Virol.,2012

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying;International Journal of Pharmaceutics;2024-09

2. Upregulation of key factors of viral entry of corona‐ and influenza viruses upon TLR3‐signaling in cells from the respiratory tract and clinical treatment options by 1,8‐Cineol;Phytotherapy Research;2024-07-17

3. Enhancing affinity of neutralizing SARS-CoV-2 nanobody through facile structure-guided mutations in CDRs;2024-05-13

4. Engineering a “muco‐trapping” ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19;Bioengineering & Translational Medicine;2024-02-07

5. Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections;Advanced Science;2024-01-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3